inebilizumab: proposed mechanism of action for treating nmosd
Published 3 years ago • 609 plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
4:41
bruce cree, md, phd, mas: inebilizumab for nmosd treatment
-
5:43
inebilizumab treatment in newly diagnosed nmosd patients
-
3:22
aan 2021 highlights: two-year efficacy and safety data with inebilizumab to treat nmosd
-
1:48
consistent efficacy of inebilizumab across newly presenting and previously treated nmosd cases
-
1:56
inebilizumab in aqp4 nmosd patients with history of immunosuppression treatment: n-momentum study
-
3:59
the safety and effective of inebilizumab in african american nmosd patients
-
3:10
bruce cree, md, phd, mas: inebilizumab in neuromyelitis optica spectrum disorder
-
6:18
soliris® (eculizumab) mechanism of action for neuromyelitis optica spectrum disorder (nmosd)
-
5:22
tips for diagnosing neuromyelitis optica spectrum disorder
-
3:31
approved treatments for neuromyelitis optica spectrum disorder
-
2:44
updates on n-momentum: inebilizumab versus placebo in patients with nmosd
-
5:12
efficacy of inebilizumab in patients with nmosd with fc receptor iii-a polymorphisms
-
8:16
distinctive attributes and efficacy of inebilizumab in nmosd
-
20:19
nmosd multidisciplinary approach webinar, 25 june 2021 - dr. suzan ibrahim noori
-
4:56
eculizumab: a review in neuromyelitis optica spectrum disorder
-
2:03
neuromyelitis optica spectrum disorder | mechanism of disease
-
2:50
chronic cognitive impairment improved after eculizumab initiation in cases of nmosd
-
6:35
neuromyelitis optica spectrum disorder (nmosd) clinical trial program
-
4:04
long term benefits of inebilizumab revealed in n momentum analysis